Foch Hospital

Median Technologies to Participate and Speak at the 2024 European Congress of Radiology (ECR), February 28 – March 3, Vienna, Austria

Retrieved on: 
Monday, February 26, 2024
Software, Radiology, Hardware, Data Management, Oncology, Biometrics, Technology, Medical Devices, Artificial Intelligence, Health Technology, Biotechnology, Other Technology, Health, Cloud, Lung cancer, Sorbonne University, Intelligence cycle, LCS, AP-HP, AI, Lung cancer screening, Lab, Hospital, Exhibition, ECR, Foch Hospital, Knowledge, Congress, Diagnosis, Deep learning, ESR, HCC, Artificial intelligence, Research, PACS

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024.
  • Philippe Grenier, Thoracic Radiologist and Head of the Artificial Intelligence project, Foch Hospital, Saint Cloud, France and Pr.
  • The European Congress of Radiology (ECR) organized by the European Society of Radiology (ESR) is the premier European event in radiology and the second largest in the world.
  • The congress conveys more than 20,000 with a split of more than 10,000 professional delegates (radiologists, technologists etc.

Surge Raises $2.6M, Secures Exclusive Licensing Agreement with Stanford to Make Surgeries Safer

Retrieved on: 
Friday, September 23, 2022
Foch Hospital, Partner, Health, Boutique, Infection, Algorithm, Wilco, CyTOF, Stanford University School of Medicine, Risk, MD, Ferdinand Foch, StartX, Industry, Lists of diseases, Patient, Physician, Disease, Technology, Stanford University, Goal, Solution, Transparency (market), Doctor of Philosophy, Pasteur Institute, Dementia, SAN, Research, Ageing, Associate, Silicon, Hospital, Mortality, Hardware Club, Immune system, Plasma, AP-HP, Biotechnology, Medicine, Medical device, Pharmaceutical industry, Anesthesiology, Surge

SAN FRANCISCO, Sept. 23, 2022 /PRNewswire/ -- Biotech and medical AI innovator Surge announced a $2.6 million round co-led by HCVC, a global early-stage fund dedicated to high-potential technology startups, and Boutique Venture Partners, a leading fund based in the Silicon Valley. Veteran angel investors, including Nicolas Godin, the COO/CFO of Cardiologs, also participated in the round. Surge was awarded the 2022 iLab grant, along with other non-dilutive grants to complete the fundraising.

Key Points: 
  • Surge was awarded the 2022 iLab grant, along with other non-dilutive grants to complete the fundraising.
  • In the summer of 2022, Surge also signed a research agreement with Stanford with the goal of developing biotech innovations.
  • The burden of complications is increasing as the population ages and the number of surgeries increases almost 5% per year (Transparency Market Research).
  • "We are proud to support Surge in its ambition to reduce the risk of postoperative complications.